LILRA4產(chǎn)品信息

英文名稱：Leukocyte immunoglobulin-like receptor subfamily A member 4

中文名稱：人白細(xì)胞免疫球蛋白樣受體亞家族A成員4

靶點(diǎn)別稱：LILRA4,CD85g,ILT7,ILT-7

物種：Human

屬性：Protein

標(biāo)記：Unconjugated

內(nèi)毒素（Endotoxin）

Less than 1.0 EU per μg by the LAL method.

純度（Purity）

>95% as determined by SDS-PAGE.

>95% as determined by SEC-MALS.

制劑（Formulation）

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

重構(gòu)方法（Reconstitution）

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存儲(chǔ)（Storage）

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

1. -20°C to -70°C for 12 months in lyophilized state;

2. -70°C for 3 months under sterile conditions after reconstitution.

LILRA4產(chǎn)品信息

白細(xì)胞免疫球蛋白樣受體亞家族A成員4（LILRA4/ILT7/CD85g）是漿細(xì)胞樣樹突狀細(xì)胞（pDCs）的標(biāo)志物，據(jù)報(bào)道，pDCs是與自身免疫性疾病相關(guān)的異常高水平IFNα的主要來(lái)源。用治療性抗體靶向LILRA4以促進(jìn)殺死這些產(chǎn)生IFNα的pDCs正在被研究作為緩解自身免疫性疾病癥狀的新方法。LILRA4是一種免疫球蛋白樣蛋白，優(yōu)先在人漿細(xì)胞樣樹突狀細(xì)胞（pDCs）表面表達(dá)。它與骨髓基質(zhì)細(xì)胞抗原2相互作用，以控制pDCs對(duì)病毒感染的Toll樣受體（TLR）驅(qū)動(dòng)的反應(yīng)。它也可能參與調(diào)節(jié)pDC與腫瘤的相互作用。pDCs是導(dǎo)致自身免疫性疾病癥狀的過(guò)量IFNα的來(lái)源。